Sheet 1 of 1

FORM PTO-144		115	DEPARTMENT OF	COMMERCE	ATTY, DOCKET NO.		APPI	JCATION NO.	1661 1 0	<u>"</u>	
(REV.7-80)					980034.417C5 10/762,210						
(DE)		THIRD SUPPLEM	ENTAI		APPLICANTS 10/702,210						
OIPE		ATION DISCLOSU		FNT	Ronald J. Berenson et al.						
<i>U</i>	-	(Use several sheets if ne		LIVI	FILING DATE GROUP ART UNIT						
NPR 18.	MA	범			January 20, 2004		164				
A NEW	- 6	/					1.0				
<u> </u>	-	/	U.S	DOCUMENTS			,				
EXMINER OF	مبت	DOCUMENT NUMBER	DATE		NAME	CL	ASS	SUBCLASS		DATE OPRIATE	
* * *,	AA										
						-					
	AB			ļ							
	AC		8								
	AD			_							
	AE		•								
_	AF										
	AG										
	АН	· · · · · · · · · · · · · · · · · · ·				1					
<u> </u>						+					
	IA.					-				-	
	AJ		<u> </u>								
			FORE	GN PATE	NT DOCUMENTS						
	,	DOCUMENT NUMBER	DATE		COUNTRY		•		TRANS	ATION	
16	AK	WO 00/50570	08/31/00	WIPO						•	
	AL							,			
	AM										
	AN							-			
	AO										
· · · · · · · · · · · · · · · · · · ·		000000	SD DDIOD :	D.T		•				,	
	5 4	OTHE	K PRIOR A	KI (Including	Author, Title, Date, Pertinent I	Pages, Etc.	.)				
	AP										
	AQ		······								
	AR								-,		
EXAMINE	L I	ton	KGO!	2	DATE CONSIDERED) (//-	39/5		<u></u>	
* EXAMINI	D.				C in tappe (AC. T.	()					
LAMINI		conformance and not conside	reu, wnether or no idered. Include co	opy of this form	nformance with MPEP 609. Drawith next communication to app	aw iine iki licani(s).	rough c	nation if not in			
\580934											

FORM PTO	1449			DEPARTMENT OF		ATTY. DOCKET NO. APPLICATION NO.						
(REV.7-80)			PATE	NT AND TRADEN	IARK OFFICE	980034.417C5 10/762,210						
			SUPPLEMENT	AL		APPLICANTS						
. II	VFOR	MA	TION DISCLOSUI	RE STATEM	ENT	Ronald J. Berenson et al.						
:		' U	(Use evenal sheets if nece	ssary)		FILING DATE	G DATE GROUP ART UNIT					
	\bot		<u>[5]</u>			January 20, 2004	1645					
					PATENT 1	DOCUMENTS					•	
*EXAMINE INITIAL	*EXAMINER DOCUMENT NUMBER INITIAL			DATE	NAME CLASS SUBCLASS			SUBCLASS	FILING DATE IF APPROPRIATE			
	A	1	ADEMARK			•					٠	
	 	+									-	
	^	В										
	A	c										
				FOREI	GN PATEN	NT DOCUMENTS						
			DOCUMENT NUMBER	DATE		COUNTRY				TRANSI		
911	1.		WO 01/62895	08/30/01	WIPO			-		YES	NO	
1	^^	/										
	^^	<u></u>	WO 02/098361	12/12/02	WIPO					,		
	A	F	WO 03/024989	03/27/03	WIPO							
	/ A	G										
<i>\</i>			OT	HER ART	(Including Auth	or, Title, Date, Pertinent Pages, E	ic)		•			
11/	1	Ŧ			 	Cell Therapy for B-CL		lood:	100(11) A	bstrac	t No	
Upc	/ A	Н	774, Novemb	er 16, 2002		••	-		. ,,		•	
1	A					vation and Expansion of						
	^	' I	Blood of Mul	tiple Myelo	na Patients Using the Xcellerate TM Process," Blood 10					0(11),		
	4	1	Abstract No.	· · · · · · · · · · · · · · · · · · ·								
	A	,	, · · · · ·	, ,		D2 Amplifies Anti-CD3					x Vivo	
		1	1	-	n of T Cells	s," <i>Blood 96</i> (11 part 2):	: 40b,	Abst	ract No. 3	834,		
	_	_	November 16									
	A	ĸ	· ·	•) vs Memory (CD45R0	•				Cells	
			_		h2 Polariza	ation Potential," Blood	<i>100</i> (1	1), A	bstract No). 944,		
		_	November 16									
	A	L		•		i-CD3 and anti-CD28 s						
			proliferation a	and IL-2R e	xpression i	n T cells," Tissue Antig	zens 5	<i>5</i> (Su	ppl. 1): 10	9, 200	0.	
	Long, S.A. et al., "Modulating T Cell Signals Using Xcyte TM Dynabeads [®] Leads to Sele							lective				
	Expansion of Antigen-Specific T Cells," Blood 102(11): 55b, Abstract No. 3922, Nove						ember					
			16, 2003.	_						_		
			Patel and Ric	kwood, "Op	timization	of conditions for speci	fic bir	iding	of antibo	ly-coa	ted	
(X	A		beads to cells	," Journal c	f Immunol	ogical Methods 184: 7)	/-80, 1	<u>995.</u>				
EXAMI	NER		ANEGO	W		DATE CONSIDERED	3/6					
* EXAM	INER:		itial if reference consider	ed, whether or no	criteria is in co	nformance with MPEP/609. Draw	line thr	ough cit	ation if not in			
L						with next communication to applic						

FORM PTO-1449 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SECOND SUPPLEMENTAL

ATTY. DOCKET NO. 980034.417C5 APPLICATION NO. 10/762,210

APPLICANTS

Ronald J. Berenson et al.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE **GROUP ART UNI** January 20, 2004 1645 **U.S. PATENT DOCUMENTS** EXAMINER DOCUMENT NUMBER SUBCLASS CLASS NAME DATE IF APPROPRIATE 02/27/01 Bell et al. 435 377 · 6,194,207 Flyer et al. 435 372.3 6,316,257 11/13/01 AC ΑD ΑE ΑF AG ΑH ΑI **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT NUMBER DATE COUNTRY YES 12/07/95 **WIPO** WO 95/32729 ΑK WO 02/072799 09/19/02 **WIPO** AN AO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) ΑP AQ AR **DATE CONSIDERED EXAMINER** * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM (9		DEPARTMENT OF ENT AND TRADEN		ATTY. DOCKET NO. APPLICATION NO.					
	,			-		APPLICANTS 10/702,210					
	INF	ORM.	ATION DISCLOSU	RE STATEM	ENT	Ronald J. Berenson et al.					
			(Use several sheets if nec			FILING DATE GROUP ART UNIT			UP ART UNIT		
						January 20, 2004 1645			15		
U.S. PATENT DOCUMENTS									_		
*EXAN		_	DOCUMENT NUMBER	DATE		NAME CLASS SUBCLASS		SUBCLASS		DATE OPRIATE	
	5,985,653 11/16/99		Armstrong et al.		435 303.1		303.1				
	вв 6,010,902 01/04/00 Ledbetter		et al.	435 328		328	_				
	<u>}</u>	ВС	6,096,532	08/01/00	Armstrong	g et al.	435		.286.5		
		BD	6,113,901	09/05/00	Bluestone		424		1.54.1		
		BE	6,129,916	10/10/00	Chang		424		179.1		
		BF	6,143,297	11/07/00	Bluestone	<u></u>	424		184.1		
		BG	6,197,298	03/06/01	Chang		424		179.1	"	
		вн	6,316,257	11/13/01	Flyer et al		435		372.3		
	_	ВІ	6,352,694	03/05/02	June et al.		424		93.71		
		ВЈ	6,355,779	03/12/02	Goodwin et al. 530 388.23						
FOREIGN PATENT DOCUMENTS											
			DOCUMENT NUMBER	DATE		COUNTRY				TRANS YES	NO NO
		вк	WO 00/02520	01/20/00	WIPO						х
		BL	WO 00/02520	01/20/00	WIPO					X	
		ВМ	WO 03/024312	03/27/03	WIPO						
		BN	WO 03/025158	03/27/03	WIPO						
		во	WO 03/034820	05/01/03	WIPO						
			OT	THER ART	Including Autho	r, Title, Date, Pertinent Pages, E	ic.)				
	1	BP				ted Terminal Maturation					
		Br			linical Immi	unology, Ricciardi-Casto	gnoli (Ed.),	Plenum Pr	ess, Ne	w
	-	y = 2, 1	York, 1997, pg		A - A	autologous T Cell Immur	41	A		. T4	В
	11	BQ	Cell Lymphoc	et al., Acend	earate. All A a (B-CLL)."	in Proceedings of the 4.	2 nd An	ipy A nual	upproach for Meeting of	r i reat the Am	ing B-
	11					December 1-5, 2000, vol					
	M		3616.							-	
	V	BR	Bretscher, P., 5 Today 13(2): 7		nal model of	f lymphocyte activation t	wenty	-one	years later,'	' Immu	nology
EXA	MINE	R	7			DATE CONSIDERED	9	/3	30/5		
* EXA	MIN		Initial inclerence consider	ed, whether or not	riteria is in con	nformance with MPEP 609. Draw	Jine the	ough ci	itation if not in		
	* EXAMINER: Initial incerence considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).										

FORM PTO-1449			DEPARTMENT OF		ATTY. DOCKET NO. APPLICATION NO.				<u> </u>	
(REV.7-80)		РАТІ	ENT AND TRADEM	IARK OFFICE	980034.417C5 10/762,210					
ı					APPLICANTS Depoild I Deponsor et al					
INFO)RM	ATION DISCLOSUI (Use several sheets if nece		ENT	Ronald J. Berenson et al.					
i		(Ose several sincers il neco	:ssary)		January 20, 2004 GROUP ART UNIT					
			· · · · · · · · · · · · · · · · · · ·		January 20, 2004		104	<u>)</u>		
			U.S.	PATENT I	DOCUMENTS					
*EXAMINER INITIAL	_	DOCUMENT NUMBER	DATE	NAME			ss	SUBCLASS	FILING IF APPRO	
	CA	2001/0031253	10/18/01	Gruenberg	3	424		93.1		
1	СВ	2002/0090362	07/11/02	Strauss		424		93.21		
	СС	2002/0182730	12/05/02	Gruenberg	3	435		375		
	CD	2003/0039650	02/27/03	Gruenberg	3	424		144.1		
-	CE	2003/0134341	07/17/03	Gruenberg	3	435		7.21		
	CF	2003/0134415	07/17/03	Gruenberg	3	435		372		
	CG	2003/0170238	09/11/03	Gruenberg	3	424		144.1		
	СН	2003/0175242	09/18/03	Gruenberg		424		93.2		
	CI	2003/0175272	09/18/03	Gruenberg				144.1		
	CI	2003/0194395	10/16/03	Gruenberg et al.				93.7		
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY				TRANSI YES	ATION NO
	CK	WO 03/043643	05/30/03	WIPO	·					
	CL	WO 03/077658	09/25/03	WIPO						
	СМ	·								
	CN									
	co.									
		Oï	THER ART	Including Autho	or. Title, Date, Pertinent Pages, E	ic.)) i	
		Carlens, S. et	al., "Ex viv	o T lympho	ocyte expansion for ret	rovira	l tran	sduction:	Influe	nce
	CP	Control of the property of the			cell expansion rates a		npho	cyte subse		
	-				logy 28: 1137-1146, 20 arr Virus-specific Cyto		Г Г	mnhooses	Decree	1000
1:116'-21	CQ				gkin's Disease Patients					
					gkiii s Disease Fatients 1: 6219-6226, August	-		ilolis loi a	1-0011-	A
N /					Therapy of Tumors:			ns of Impr	aved.	
	CR			-	r Therapy of Tumors. T Reviews in Immunolog			_		
EXAMINE	R	(Answ	Call	2	DATE CONSIDERED	1/1	201	1		
* EXAMINI	R:	Initial if reference consider	ed, whether or not	criteria is in cor	nformance with MPEP 609. Draw	line thr	ough ci	tation if not in		
	EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).									

FORM PTO-14	49	U.S	DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO.		APPLICATION NO.			
(REV.7-80)		PA	TENT AND TRADEN	AARK OFFICE	980034.417C5 10/762,210					
					APPLICANTS					
INI	ORM	ATION DISCLOSU		ENT	Ronald J. Berenson et al.					
		(Use several sheets if ne	cessary)		FILING DATE GROUP ART UNIT					
					January 20, 2004		1645			
		_	U.S.	PATENT	DOCUMENTS	٠				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS		DATE OPRIATE	
	DA									
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS	LATION	
	DB			· · · · · ·						
•	/	0	THER ART	(Including Autho	or, Title, Date, Pertinent Pages. Et	ıc.)		I		
1.	/ 50				ration of Anti-CD28 Co		lation Deter	nine		
	′ DC	' '	•							
	1	l I	•	•	age-Tropic Strains of Human Immunodeficiency Virus gy, 73(11):9337-9347, November 1999.					
					eveals significant reper			na in wi	120	
1	DD			•	mmunology 9(8): 1073			ng in vii	110	
	+							·- CD0	+	
- 1	DE				ell culture bags to expar		•			
					of Immunological Metho		· · · · · · · · · · · · · · · · · · ·		-	
1	DF	i -	•		II autoreactivity by anor		-			
		and its MIC	ligands in rh	eumatoid a	rthritis," <i>Proceedings o</i>	f the N	lational Acad	lemy of	•	
		Sciences 100	(16): 9452-9	457, Auge	st 5, 2003.					
}	DG	Haanen et al	, "Selective	Expansion	of Cross-reactive CD8	⁺ Mem	ory T Cells b	y Viral		
		Variants," J.	Exp. Med. 1.	<i>90</i> (9): 1319	9-1328, November 1, 19	999.				
					tform Process for the C		lanufacture o	f Activ	ated T	
	DH		-		vith Cancer and Immun					
- 1					nerican Society of Hem	-			60	
- 1					, part 1, abstract # 3630	•	y, Sair Franc	1300,	,	
	-				er cell function after T-		mlatina than		tin a	
	Di		•	· •	ood 99(11): 4053-4062,			py affec	ung	
	1				expansion of T cells fro			s with (CLL:	
	DJ				ution," Cytotherapy 2(3		•			
^	дK	lezzi et al., "	The Duration	of Antige	nic Stimulation Determ	ines th	ne Fate of Na	ive and		
\mathbb{N}	Y	Effector T C	ells," <i>Immun</i>	ity 8: 89-95	5, January 1998.					
	DL				ens, IL-2 and Anti-CD3			-Cell		
EVALUE		Receptor Vβ	Kepertoire,"	Scand. J. I	Immunol. 43: 652-661,	1996.	1			
EXAMIN	ek 	LANK	FORD		DATE CONSIDERED	///	30/5			
* EXAMIN	ER:	Initial if reference conside	red, whether or not	criteria is in cor	formance with MPEP 609. Draw	line throu	igh citation if not i	n		

FORM PTO	-1449		U.S.	DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO. APPLICATION NO.					
(REV.7-80)			PAT	ENT AND TRADEM	ARK OFFICE	980034.417C5 10/762,210					
						APPLICANTS .					
יו	NFOR	MAT	ION DISCLOSU	RE STATEM	ENT	Ronald J. Berenson et	t al.			•	
			(Use several sheets if nec			FILING DATE GROUP ART UNIT					
}						January 20, 2004		164	5		
 						·					
AEN - 1 - 1 - 1	= -			U.S.	PATENT	DOCUMENTS			ı	FU 110 D 4 TE	
*EXAMINE INITIAL	- 1	D	OCUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS	FILING DATE IF APPROPRIATE	
	EA										
				FOREI	GN PATEN	NT DOCUMENTS	· ·		· · · · · · · · · · · · · · · · · · ·		
			DOCUMENT DATE			COUNTRY				TRANSLATION YES NO	
	EE										
				•						.	
•	1		O 2	THER ART	(Including Autho	or, Title, Date, Pertinent Pages, Et	tc.)				
	EC	,	June et al., "	The B7 and	CD28 recep	otor families," Immunol	logy I	oday	y <i>15</i> (7): 32	1-331, 1994	
	EI	\prod	Kalamasz, D	et al., "Sto	rage Shipm	ent of Freshly Harveste	d or (Cryo	preserved	Xcellerate™	
1	EL	'	Activated T	Cells for Cli	nical Appli	plications," in Proceedings of the 42 nd Annual Meeting of					
		1	the American	Society of I	Hematology	y, San Francisco, Decen	nber	1-5, 2	2000, vol.	96, no. 11,	
		İ	part 2, abstra	ct # 5113.	•						
			Kato et al., "	Gene Transf	er of CD40	-Ligand Induces Autolo	ogous	Imn	nune Reco	gnition of	
	EE					Cells," J. Clin. Invest. 1	_			_	
			Kluin-Nelem	ans, H.C. et	al., "Corre	ction of Abnormal T-C	ell Re	cept	or Reperto	ire During	
	EF	ŀ	Interferon-a	Therapy in P	atients Wit	th Hairy Cell Leukemia	," <i>Bla</i>	Blood 91(11): 4224-4231,			
			June 1998.	•							
	EC	T	Krawczyk et	al., "Cbl-b l	s a Negativ	e Regulator of Receptor	r Clu	steri	ng and Rai	ft	
	EC	'	Aggregation	in T Cells,"	Immunity I	13: 463-473, October 20	000.				
	EH		Lanzavecchia	a, A., "The F	Role of Den	dritic Cells in the Gene	eratio	n of]	Effector ar	nd Memory	
	['	Cell Respons	es," from T	he Midwint	er Conference of Immu	nolog	ists,	January 22	2-25, 2000,	
			available at v	vww.midwc	<u>onfimmunc</u>	ol.org/Midwinter00/sess	sions/	lanz	avecchia.h	<u>tml</u> .	
	EI		Larsson, S. e	t al., "Produ	ctive Cytor	negalovirus (CMV) Inf	ection	Exc	clusively in	1 CD13-	
	E1		Positive Peri	pheral Blood	l Mononuc	lear Cells from CMV-I	nfecte	d In	dividuals,'		
			Transplantat	ion, 65(3):4	11-415, Fel	bruary 15, 1998.					
	T.,					⁺ CD4 ⁺ T regulatory ce	ells su	ppre	ss naive ar	nd memory	
	EJ		T cell prolife	ration and c	an be expai	nded in vitro without lo	ss of	func	tion," <i>J. E</i> :	xp. Med.	
			193(11): 129	5-1301, Jun	e 2001.						
			Li, Q. et al.,	Expanded 1	Tumor-reac	tive CD4 ⁺ T-Cell Resp	onses	to H	luman Can	cers Induced	
]	EK	•				Activation," Clinical C					
1			February 199								
14	ÆL		Li, Q. et al.,	'Immunolog	ical Effects	s of BCG as an Adjuva	nt in A	Auto	logous Tui	mor _	
			Vaccines," C	linical Imm	unology 94	(1): 64-72, January 200	0		1		
EXAMI	NER		CANC	FORD	,	DATE CONSIDERED	6	//	30/5		
* EXAM	IINER:					nformance with MPEP 609. Draw			itation if not in		
L	conformance and not considered. Include copy of this form with next communication to applicant(s).										

Sheet <u>6</u> of <u>7</u>

(REV.7-80) PATENT AND TRADEMARK OFFICE 980034.417C5 APPLICANTS Ronald J. Berenson et al. FILING DATE GROUP ART UNIT January 20, 2004 1645									
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) APPLICANTS Ronald J. Berenson et al. FILING DATE GROUP ART UNIT									
(Use several sheets if necessary) FILING DATE GROUP ART UNIT									
(Use several sheets if necessary) FILING DATE GROUP ART UNIT									
January 20, 2004									
1 January 20, 2004 1 1043									
U.S. PATENT DOCUMENTS									
*EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE									
INITIAL I FAPPROPRIATE									
FA									
FOREIGN PATENT DOCUMENTS									
DOCUMENT DATE COUNTRY TRANSLATION									
NUMBER DATE COUNTRY YES NO									
FB									
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
Liebowitz et al., "Costimulatory approaches to adoptive immunotherapy," Current Opinion in									
Oncology 10: 533-541, 1998.									
Lin and Welsh, "Stability and Diveristy of T Cell Receptor Repertoire Usage during Lymphocytic									
Choriomenigitis Virus Infection of Mice, "Journal of Experimental Medicine 188(11): 1993-2005									
December 7, 1998.									
Lopez, R.D. et al., "CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in									
vitro expansion of CD56 ⁺ T cells," Cancer Immunol. Immunother. 49: 629-640, 2001.									
Mariani, S. et al., "Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion,"									
British Journal of Hematology 113: 1051-1059, 2001.									
Marijt and Falkenburg, "Specific T Cell Therapy in Leukemia," Journal of Hematotherapy & Sten									
FG Cell Research 10: 493-500, 2001.									
Moebius, U. et al., "T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in									
chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T									
cell clones," Eur. J. Immunol. 20: 889-896, 1990.									
Nijhuis, M. et al., "Stochastic processes strongly influence HIV-1 evolution during suboptimal									
protease-inhibitor therapy," Proc. Natl. Acad. Sci. USA 95: 14441-14446, November 1998.									
Polanski, M. et al., "Xcellerate(: A Closed, Scalable Process for the GMP Manufacture of Stable									
Activated I Cells," in Proceedings of the 13" Annual Scientific Meeting of the Society for									
Biological Therapy, Seattle, October 26-29, 2000, and Journal of Immunotherapy, (23)5:599,									
September 2000.									
Ranheim and Kipps, "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B									
Cells through a CD40-dependent Signal," J. Exp. Med. 177: 925-935, April 1993. Ria, F. et al., "Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis									
Ala, F. et al., Molecular Characterization of the 1 Cell Repetitive Osing Mundio-scope Analysis and its Possible Implementation in Clinical Practice," Current Molecular Medicine 1: 297-304,									
2001.									
EXAMINER LANCIONS DATE CONSIDERED 9/30/5									
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).									

FORM	PTO-1449)	. U.S.	DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO. APPLICATION NO.						
(REV.7	7-80)		PAT	ENT AND TRADEM	1ARK OFFICE	980034.417C5 10/762,210						
				•		APPLICANTS						
	INFO	DRM.	ATION DISCLOSU	RE STATEM	ENT	Ronald J. Berenson e	t al.					
1			(Use several sheets if nec	essary)		FILING DATE GROUP ART UNIT						
ł						January 20, 2004		164	5			
	U.S. PATENT DOCUMENTS											
	MINER TIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	ss	SUBCLASS	FILING DATE IF APPROPRIATE		
		GA										
	FOREIGN PATENT DOCUMENTS											
			DOCUMENT NUMBER	DATE		COUNTRY				TRANSLATION YES NO		
		GB				· · · · · · · · · · · · · · · · · · ·				TES NO		
•			O	THER ART	(Including Author	or, Title, Date, Pertinent Pages, E	(a.)		· · · · · · · · · · · · · · · · · · ·	<u> </u>		
									(2), 114 1	22		
11	1	∕cc	l l		ен тпегару	of Leukemia," Cancer	Conti	roi y	(2): 114-1	22,		
0,2			March/April		Carlant	C - C - C D	- Т	T	-14	- T - 4 -		
	•	GD				ivo Expansion of Prim	•		_			
	+					ch and Human Retrovii						
	1	GE				T Cell Proliferation ar						
						ated Autologous B Cell	s," Cli	inica	il Immuno	logy and		
			Immunopath				 -					
		GF		•	-	tein-Barr Virus Cytotox						
			_		-	ations for Immune The	rapy,"	Ame	erican Jour	rnal of		
			Pathology 16									
		GG				on of a Peripheral Bloc						
.						-Selectin During Prima				in Renal		
	-					ion Proceedings 30: 39		_				
1		GН	·	•	-	ooptosis in Anti-CD3-T			-			
				by Immuno	suppressiv	e Drugs," Transplantai	ion Pi	roce	edings 32:	1992-1994,		
			2000.									
		GI			_	oliferation causing pure			_			
		Ŭ.				sful treatment with cyc	-		_			
			abrogation of	erythroid c	olony-supp	ressing activity," Britis	h Jour	rnal	of Haemai	tology 101:		
			335-337, 199							•		
		GJ				ice Exhibit A Progressi						
		0.5	Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4+									
			Cell Activity	," The Journ	al of Immu	mology 148(2): 648-65	5, Jani	uary	15, 1992.			
		σĸ										
Y		GL		•			•	_				
EXA	MINE	R	CANC	CAD 1-		DATE CONSIDERED		di	1-71/			
* EV	A N 4 I N 11	D.				face and Albert too. 5	.):= - <1	1	<u> 50 / 5</u>			
- CA	* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).											